Age Related Macular Degeneration Market By Drug Type (Aflibercept, Ranibizumab, Others) , By Disease Type (Wet Age Related Macular Degeneration (AMD) , Dry Age Related Macular Degeneration (AMD)) By Distribution Channel (Hospital Pharmacy, Retail Pharmacy

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $5,820	216 Pages	Allied Market Research	July, 2024	ALMR19230025

Best Price Guarantee
Price	from $5,820
Length	216 Pages
Publisher	Allied Market Research
Published Date	July, 2024
SKU	ALMR19230025

Age Related Macular Degeneration Market By Drug Type (Aflibercept, Ranibizumab, Others) , By Disease Type (Wet Age Related Macular Degeneration (AMD) , Dry Age Related Macular Degeneration (AMD)) By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) : Global Opportunity Analysis and Industry Forecast, 2024-2033

Age Related Macular Degeneration Market
The age related macular degeneration market was valued at $10.0 billion in 2023 and is projected to reach $16.2 billion by 2033, growing at a CAGR of 5% from 2024 to 2033.
Age related macular degeneration is a visual impairment in which the central portion of the retina, known as macula, deteriorates. Beginning with slight blurred vision, the disease eventually leads to loss of central eyesight. There are two categories of the disease: dry (atrophic) and wet (neovascular). Gradual thinning of the macula occurs in dry macular degeneration, whereas wet macular degeneration happens due to abnormal growth of blood vessels under the retina.
Exponential increase in the aging population and rise in prevalence of the disease are the key drivers of the age related macular degeneration market. In addition, advancements in diagnostic techniques are leading to early detection and timely treatment of the disease, thereby augmenting the market development. In recent times, AI and deep learning are revolutionizing the landscape of age related macular degeneration diagnosis and treatment. The technology helps in precise detection of the eye condition and assesses the risk pertaining to the progression of the disease to advanced stages.
However, in case of disease advancement to high stages, treatment procedures exhibit limited to no efficacy, thereby restraining the growth of the age related macular degeneration market. Moreover, the high expense of purchasing medications essential for curing the disease, such as anti-vascular endothelial growth factor injections, constraints several patients from undergoing the treatment. This hampers the development of the market. According to an article published by the UK-based scientific journals publisher—BioMed Central— age related macular degeneration is one of the leading causes of vision loss and by 2040, the disease is anticipated to impact 288 million individuals.

Segment Review

The age related macular degeneration market is segmented into drug type, disease type, distribution channel, and region. On the basis of drug type, the market is divided into aflibercept, ranibizumab, and others. Depending on disease type, it is bifurcated into wet age related macular degeneration (AMD) and dry age related macular degeneration (AMD). As per distribution channel, it is classified into hospital pharmacy, retail pharmacy, and online pharmacy. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of drug type, the aflibercept segment dominates the age related macular degeneration market.
Depending on disease type, the wet age-related macular degeneration (AMD) segment acquires a significant share of the market.
As per distribution channel, the hospital pharmacy segment leads in the market.
Region wise, the market exhibits robust growth in North America.

Competition Analysis

The leading players operating in the global age related macular degeneration market include Regeneron Pharmaceuticals Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Biogen, Bayer AG, Coherus Biosciences Inc, Sanofi, Apellis Pharmaceuticals, Bausch Health Companies Inc., and Ionis Pharmaceuticals, Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.

Key Market Segments

By Drug Type

Aflibercept
Ranibizumab
Others

By Disease Type

Wet Age Related Macular Degeneration (AMD)
Dry Age Related Macular Degeneration (AMD)

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By Region

North America
U.S.
Canada
Mexico
Europe
France
Germany
Italy
Spain
UK
Rest of Europe
Asia-Pacific
China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
LAMEA
Brazil
South Africa
Saudi Arabia
Rest of LAMEA
Key Market Players
Regeneron Pharmaceuticals Inc.
Novartis AG
F. Hoffmann-La Roche Ltd.
Biogen
Bayer AG
Coherus Biosciences Inc
Sanofi
Apellis Pharmaceuticals
Bausch Health Companies Inc.
Ionis Pharmaceuticals, Inc

CHAPTER 1: INTRODUCTION: 1.1. Report Description; 1.2. Key Market Segments; 1.3. Key Benefits; 1.4. Research Methodology; 1.4.1. Primary Research; 1.4.2. Secondary Research; 1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY: 2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE: 3.1. Market Definition and Scope; 3.2. Key Findings; 3.2.1. Top Investment Pockets; 3.2.2. Top Winning Strategies; 3.3. Porter's Five Forces Analysis; 3.3.1. Bargaining Power of Suppliers; 3.3.2. Threat of New Entrants; 3.3.3. Threat of Substitutes; 3.3.4. Competitive Rivalry; 3.3.5. Bargaining Power among Buyers; 3.4. Market Dynamics; 3.4.1. Drivers; 3.4.2. Restraints; 3.4.3. Opportunities
CHAPTER 4: AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE: 4.1. Market Overview; 4.1.1 Market Size and Forecast, By Drug Type; 4.2. Aflibercept; 4.2.1. Key Market Trends, Growth Factors and Opportunities; 4.2.2. Market Size and Forecast, By Region; 4.2.3. Market Share Analysis, By Country; 4.3. Ranibizumab; 4.3.1. Key Market Trends, Growth Factors and Opportunities; 4.3.2. Market Size and Forecast, By Region; 4.3.3. Market Share Analysis, By Country; 4.4. Others; 4.4.1. Key Market Trends, Growth Factors and Opportunities; 4.4.2. Market Size and Forecast, By Region; 4.4.3. Market Share Analysis, By Country
CHAPTER 5: AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE: 5.1. Market Overview; 5.1.1 Market Size and Forecast, By Disease Type; 5.2. Wet Age Related Macular Degeneration (AMD); 5.2.1. Key Market Trends, Growth Factors and Opportunities; 5.2.2. Market Size and Forecast, By Region; 5.2.3. Market Share Analysis, By Country; 5.3. Dry Age Related Macular Degeneration (AMD); 5.3.1. Key Market Trends, Growth Factors and Opportunities; 5.3.2. Market Size and Forecast, By Region; 5.3.3. Market Share Analysis, By Country
CHAPTER 6: AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL: 6.1. Market Overview; 6.1.1 Market Size and Forecast, By Distribution Channel; 6.2. Hospital Pharmacy; 6.2.1. Key Market Trends, Growth Factors and Opportunities; 6.2.2. Market Size and Forecast, By Region; 6.2.3. Market Share Analysis, By Country; 6.3. Retail Pharmacy; 6.3.1. Key Market Trends, Growth Factors and Opportunities; 6.3.2. Market Size and Forecast, By Region; 6.3.3. Market Share Analysis, By Country; 6.4. Online Pharmacy; 6.4.1. Key Market Trends, Growth Factors and Opportunities; 6.4.2. Market Size and Forecast, By Region; 6.4.3. Market Share Analysis, By Country
CHAPTER 7: AGE RELATED MACULAR DEGENERATION MARKET, BY REGION: 7.1. Market Overview; 7.1.1 Market Size and Forecast, By Region; 7.2. North America; 7.2.1. Key Market Trends and Opportunities; 7.2.2. Market Size and Forecast, By Drug Type; 7.2.3. Market Size and Forecast, By Disease Type; 7.2.4. Market Size and Forecast, By Distribution Channel; 7.2.5. Market Size and Forecast, By Country; 7.2.6. U.S. Age Related Macular Degeneration Market; 7.2.6.1. Market Size and Forecast, By Drug Type; 7.2.6.2. Market Size and Forecast, By Disease Type; 7.2.6.3. Market Size and Forecast, By Distribution Channel; 7.2.7. Canada Age Related Macular Degeneration Market; 7.2.7.1. Market Size and Forecast, By Drug Type; 7.2.7.2. Market Size and Forecast, By Disease Type; 7.2.7.3. Market Size and Forecast, By Distribution Channel; 7.2.8. Mexico Age Related Macular Degeneration Market; 7.2.8.1. Market Size and Forecast, By Drug Type; 7.2.8.2. Market Size and Forecast, By Disease Type; 7.2.8.3. Market Size and Forecast, By Distribution Channel; 7.3. Europe; 7.3.1. Key Market Trends and Opportunities; 7.3.2. Market Size and Forecast, By Drug Type; 7.3.3. Market Size and Forecast, By Disease Type; 7.3.4. Market Size and Forecast, By Distribution Channel; 7.3.5. Market Size and Forecast, By Country; 7.3.6. France Age Related Macular Degeneration Market; 7.3.6.1. Market Size and Forecast, By Drug Type; 7.3.6.2. Market Size and Forecast, By Disease Type; 7.3.6.3. Market Size and Forecast, By Distribution Channel; 7.3.7. Germany Age Related Macular Degeneration Market; 7.3.7.1. Market Size and Forecast, By Drug Type; 7.3.7.2. Market Size and Forecast, By Disease Type; 7.3.7.3. Market Size and Forecast, By Distribution Channel; 7.3.8. Italy Age Related Macular Degeneration Market; 7.3.8.1. Market Size and Forecast, By Drug Type; 7.3.8.2. Market Size and Forecast, By Disease Type; 7.3.8.3. Market Size and Forecast, By Distribution Channel; 7.3.9. Spain Age Related Macular Degeneration Market; 7.3.9.1. Market Size and Forecast, By Drug Type; 7.3.9.2. Market Size and Forecast, By Disease Type; 7.3.9.3. Market Size and Forecast, By Distribution Channel; 7.3.10. UK Age Related Macular Degeneration Market; 7.3.10.1. Market Size and Forecast, By Drug Type; 7.3.10.2. Market Size and Forecast, By Disease Type; 7.3.10.3. Market Size and Forecast, By Distribution Channel; 7.3.11. Rest Of Europe Age Related Macular Degeneration Market; 7.3.11.1. Market Size and Forecast, By Drug Type; 7.3.11.2. Market Size and Forecast, By Disease Type; 7.3.11.3. Market Size and Forecast, By Distribution Channel; 7.4. Asia-Pacific; 7.4.1. Key Market Trends and Opportunities; 7.4.2. Market Size and Forecast, By Drug Type; 7.4.3. Market Size and Forecast, By Disease Type; 7.4.4. Market Size and Forecast, By Distribution Channel; 7.4.5. Market Size and Forecast, By Country; 7.4.6. China Age Related Macular Degeneration Market; 7.4.6.1. Market Size and Forecast, By Drug Type; 7.4.6.2. Market Size and Forecast, By Disease Type; 7.4.6.3. Market Size and Forecast, By Distribution Channel; 7.4.7. Japan Age Related Macular Degeneration Market; 7.4.7.1. Market Size and Forecast, By Drug Type; 7.4.7.2. Market Size and Forecast, By Disease Type; 7.4.7.3. Market Size and Forecast, By Distribution Channel; 7.4.8. India Age Related Macular Degeneration Market; 7.4.8.1. Market Size and Forecast, By Drug Type; 7.4.8.2. Market Size and Forecast, By Disease Type; 7.4.8.3. Market Size and Forecast, By Distribution Channel; 7.4.9. South Korea Age Related Macular Degeneration Market; 7.4.9.1. Market Size and Forecast, By Drug Type; 7.4.9.2. Market Size and Forecast, By Disease Type; 7.4.9.3. Market Size and Forecast, By Distribution Channel; 7.4.10. Australia Age Related Macular Degeneration Market; 7.4.10.1. Market Size and Forecast, By Drug Type; 7.4.10.2. Market Size and Forecast, By Disease Type; 7.4.10.3. Market Size and Forecast, By Distribution Channel; 7.4.11. Rest of Asia-Pacific Age Related Macular Degeneration Market; 7.4.11.1. Market Size and Forecast, By Drug Type; 7.4.11.2. Market Size and Forecast, By Disease Type; 7.4.11.3. Market Size and Forecast, By Distribution Channel; 7.5. LAMEA; 7.5.1. Key Market Trends and Opportunities; 7.5.2. Market Size and Forecast, By Drug Type; 7.5.3. Market Size and Forecast, By Disease Type; 7.5.4. Market Size and Forecast, By Distribution Channel; 7.5.5. Market Size and Forecast, By Country; 7.5.6. Brazil Age Related Macular Degeneration Market; 7.5.6.1. Market Size and Forecast, By Drug Type; 7.5.6.2. Market Size and Forecast, By Disease Type; 7.5.6.3. Market Size and Forecast, By Distribution Channel; 7.5.7. South Africa Age Related Macular Degeneration Market; 7.5.7.1. Market Size and Forecast, By Drug Type; 7.5.7.2. Market Size and Forecast, By Disease Type; 7.5.7.3. Market Size and Forecast, By Distribution Channel; 7.5.8. Saudi Arabia Age Related Macular Degeneration Market; 7.5.8.1. Market Size and Forecast, By Drug Type; 7.5.8.2. Market Size and Forecast, By Disease Type; 7.5.8.3. Market Size and Forecast, By Distribution Channel; 7.5.9. Rest of LAMEA Age Related Macular Degeneration Market; 7.5.9.1. Market Size and Forecast, By Drug Type; 7.5.9.2. Market Size and Forecast, By Disease Type; 7.5.9.3. Market Size and Forecast, By Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE: 8.1. Introduction; 8.2. Top Winning Strategies; 8.3. Product Mapping Of Top 10 Player; 8.4. Competitive Dashboard; 8.5. Competitive Heatmap; 8.6. Top Player Positioning, 2023
CHAPTER 9: COMPANY PROFILES: 9.1. Regeneron Pharmaceuticals Inc.; 9.1.1. Company Overview; 9.1.2. Key Executives; 9.1.3. Company Snapshot; 9.1.4. Operating Business Segments; 9.1.5. Product Portfolio; 9.1.6. Business Performance; 9.1.7. Key Strategic Moves and Developments; 9.2. Novartis AG; 9.2.1. Company Overview; 9.2.2. Key Executives; 9.2.3. Company Snapshot; 9.2.4. Operating Business Segments; 9.2.5. Product Portfolio; 9.2.6. Business Performance; 9.2.7. Key Strategic Moves and Developments; 9.3. F. Hoffmann-La Roche Ltd.; 9.3.1. Company Overview; 9.3.2. Key Executives; 9.3.3. Company Snapshot; 9.3.4. Operating Business Segments; 9.3.5. Product Portfolio; 9.3.6. Business Performance; 9.3.7. Key Strategic Moves and Developments; 9.4. Biogen; 9.4.1. Company Overview; 9.4.2. Key Executives; 9.4.3. Company Snapshot; 9.4.4. Operating Business Segments; 9.4.5. Product Portfolio; 9.4.6. Business Performance; 9.4.7. Key Strategic Moves and Developments; 9.5. Bayer AG; 9.5.1. Company Overview; 9.5.2. Key Executives; 9.5.3. Company Snapshot; 9.5.4. Operating Business Segments; 9.5.5. Product Portfolio; 9.5.6. Business Performance; 9.5.7. Key Strategic Moves and Developments; 9.6. Coherus Biosciences Inc; 9.6.1. Company Overview; 9.6.2. Key Executives; 9.6.3. Company Snapshot; 9.6.4. Operating Business Segments; 9.6.5. Product Portfolio; 9.6.6. Business Performance; 9.6.7. Key Strategic Moves and Developments; 9.7. Sanofi; 9.7.1. Company Overview; 9.7.2. Key Executives; 9.7.3. Company Snapshot; 9.7.4. Operating Business Segments; 9.7.5. Product Portfolio; 9.7.6. Business Performance; 9.7.7. Key Strategic Moves and Developments; 9.8. Apellis Pharmaceuticals; 9.8.1. Company Overview; 9.8.2. Key Executives; 9.8.3. Company Snapshot; 9.8.4. Operating Business Segments; 9.8.5. Product Portfolio; 9.8.6. Business Performance; 9.8.7. Key Strategic Moves and Developments; 9.9. Bausch Health Companies Inc.; 9.9.1. Company Overview; 9.9.2. Key Executives; 9.9.3. Company Snapshot; 9.9.4. Operating Business Segments; 9.9.5. Product Portfolio; 9.9.6. Business Performance; 9.9.7. Key Strategic Moves and Developments; 9.10. Ionis Pharmaceuticals, Inc; 9.10.1. Company Overview; 9.10.2. Key Executives; 9.10.3. Company Snapshot; 9.10.4. Operating Business Segments; 9.10.5. Product Portfolio; 9.10.6. Business Performance; 9.10.7. Key Strategic Moves and Developments; TABLE 1. GLOBAL AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION); TABLE 2. AGE RELATED MACULAR DEGENERATION MARKET FOR AFLIBERCEPT, BY REGION, 2024 - 2033 ($BILLION); TABLE 3. AGE RELATED MACULAR DEGENERATION MARKET FOR RANIBIZUMAB, BY REGION, 2024 - 2033 ($BILLION); TABLE 4. AGE RELATED MACULAR DEGENERATION MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION); TABLE 5. GLOBAL AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION); TABLE 6. AGE RELATED MACULAR DEGENERATION MARKET FOR WET AGE RELATED MACULAR DEGENERATION (AMD), BY REGION, 2024 - 2033 ($BILLION); TABLE 7. AGE RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION (AMD), BY REGION, 2024 - 2033 ($BILLION); TABLE 8. GLOBAL AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION); TABLE 9. AGE RELATED MACULAR DEGENERATION MARKET FOR HOSPITAL PHARMACY, BY REGION, 2024 - 2033 ($BILLION); TABLE 10. AGE RELATED MACULAR DEGENERATION MARKET FOR RETAIL PHARMACY, BY REGION, 2024 - 2033 ($BILLION); TABLE 11. AGE RELATED MACULAR DEGENERATION MARKET FOR ONLINE PHARMACY, BY REGION, 2024 - 2033 ($BILLION); TABLE 12. AGE RELATED MACULAR DEGENERATION MARKET, BY REGION, 2024 - 2033 ($BILLION); TABLE 13. NORTH AMERICA AGE RELATED MACULAR DEGENERATION MARKET, BY COUNTRY, 2024 - 2033 ($BILLION); TABLE 14. NORTH AMERICA AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION); TABLE 15. NORTH AMERICA AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION); TABLE 16. NORTH AMERICA AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION); TABLE 17. U.S. AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION); TABLE 18. U.S. AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION); TABLE 19. U.S. AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION); TABLE 20. CANADA AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION); TABLE 21. CANADA AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION); TABLE 22. CANADA AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION); TABLE 23. MEXICO AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION); TABLE 24. MEXICO AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION); TABLE 25. MEXICO AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION); TABLE 26. EUROPE AGE RELATED MACULAR DEGENERATION MARKET, BY COUNTRY, 2024 - 2033 ($BILLION); TABLE 27. EUROPE AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION); TABLE 28. EUROPE AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION); TABLE 29. EUROPE AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION); TABLE 30. FRANCE AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION); TABLE 31. FRANCE AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION); TABLE 32. FRANCE AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION); TABLE 33. GERMANY AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION); TABLE 34. GERMANY AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION); TABLE 35. GERMANY AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION); TABLE 36. ITALY AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION); TABLE 37. ITALY AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION); TABLE 38. ITALY AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION); TABLE 39. SPAIN AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION); TABLE 40. SPAIN AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION); TABLE 41. SPAIN AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION); TABLE 42. UK AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION); TABLE 43. UK AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION); TABLE 44. UK AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION); TABLE 45. REST OF EUROPE AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION); TABLE 46. REST OF EUROPE AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION); TABLE 47. REST OF EUROPE AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION); TABLE 48. ASIA-PACIFIC AGE RELATED MACULAR DEGENERATION MARKET, BY COUNTRY, 2024 - 2033 ($BILLION); TABLE 49. ASIA-PACIFIC AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION); TABLE 50. ASIA-PACIFIC AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION); TABLE 51. ASIA-PACIFIC AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION); TABLE 52. CHINA AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION); TABLE 53. CHINA AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION); TABLE 54. CHINA AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION); TABLE 55. JAPAN AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION); TABLE 56. JAPAN AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION); TABLE 57. JAPAN AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION); TABLE 58. INDIA AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION); TABLE 59. INDIA AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION); TABLE 60. INDIA AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION); TABLE 61. SOUTH KOREA AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION); TABLE 62. SOUTH KOREA AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION); TABLE 63. SOUTH KOREA AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION); TABLE 64. AUSTRALIA AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION); TABLE 65. AUSTRALIA AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION); TABLE 66. AUSTRALIA AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION); TABLE 67. REST OF ASIA-PACIFIC AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION); TABLE 68. REST OF ASIA-PACIFIC AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION); TABLE 69. REST OF ASIA-PACIFIC AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION); TABLE 70. LAMEA AGE RELATED MACULAR DEGENERATION MARKET, BY COUNTRY, 2024 - 2033 ($BILLION); TABLE 71. LAMEA AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION); TABLE 72. LAMEA AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION); TABLE 73. LAMEA AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION); TABLE 74. BRAZIL AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION); TABLE 75. BRAZIL AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION); TABLE 76. BRAZIL AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION); TABLE 77. SOUTH AFRICA AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION); TABLE 78. SOUTH AFRICA AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION); TABLE 79. SOUTH AFRICA AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION); TABLE 80. SAUDI ARABIA AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION); TABLE 81. SAUDI ARABIA AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION); TABLE 82. SAUDI ARABIA AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION); TABLE 83. REST OF LAMEA AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION); TABLE 84. REST OF LAMEA AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION); TABLE 85. REST OF LAMEA AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION); TABLE 86. REGENERON PHARMACEUTICALS INC.: KEY EXECUTIVES; TABLE 87. REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT; TABLE 88. REGENERON PHARMACEUTICALS INC.: OPERATING SEGMENTS; TABLE 89. REGENERON PHARMACEUTICALS INC.: PRODUCT PORTFOLIO; TABLE 90. REGENERON PHARMACEUTICALS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 91. NOVARTIS AG: KEY EXECUTIVES; TABLE 92. NOVARTIS AG: COMPANY SNAPSHOT; TABLE 93. NOVARTIS AG: OPERATING SEGMENTS; TABLE 94. NOVARTIS AG: PRODUCT PORTFOLIO; TABLE 95. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 96. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES; TABLE 97. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT; TABLE 98. F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS; TABLE 99. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO; TABLE 100. F. HOFFMANN-LA ROCHE LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 101. BIOGEN: KEY EXECUTIVES; TABLE 102. BIOGEN: COMPANY SNAPSHOT; TABLE 103. BIOGEN: OPERATING SEGMENTS; TABLE 104. BIOGEN: PRODUCT PORTFOLIO; TABLE 105. BIOGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 106. BAYER AG: KEY EXECUTIVES; TABLE 107. BAYER AG: COMPANY SNAPSHOT; TABLE 108. BAYER AG: OPERATING SEGMENTS; TABLE 109. BAYER AG: PRODUCT PORTFOLIO; TABLE 110. BAYER AG: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 111. COHERUS BIOSCIENCES INC: KEY EXECUTIVES; TABLE 112. COHERUS BIOSCIENCES INC: COMPANY SNAPSHOT; TABLE 113. COHERUS BIOSCIENCES INC: OPERATING SEGMENTS; TABLE 114. COHERUS BIOSCIENCES INC: PRODUCT PORTFOLIO; TABLE 115. COHERUS BIOSCIENCES INC: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 116. SANOFI: KEY EXECUTIVES; TABLE 117. SANOFI: COMPANY SNAPSHOT; TABLE 118. SANOFI: OPERATING SEGMENTS; TABLE 119. SANOFI: PRODUCT PORTFOLIO; TABLE 120. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 121. APELLIS PHARMACEUTICALS: KEY EXECUTIVES; TABLE 122. APELLIS PHARMACEUTICALS: COMPANY SNAPSHOT; TABLE 123. APELLIS PHARMACEUTICALS: OPERATING SEGMENTS; TABLE 124. APELLIS PHARMACEUTICALS: PRODUCT PORTFOLIO; TABLE 125. APELLIS PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 126. BAUSCH HEALTH COMPANIES INC.: KEY EXECUTIVES; TABLE 127. BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT; TABLE 128. BAUSCH HEALTH COMPANIES INC.: OPERATING SEGMENTS; TABLE 129. BAUSCH HEALTH COMPANIES INC.: PRODUCT PORTFOLIO; TABLE 130. BAUSCH HEALTH COMPANIES INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 131. IONIS PHARMACEUTICALS, INC: KEY EXECUTIVES; TABLE 132. IONIS PHARMACEUTICALS, INC: COMPANY SNAPSHOT; TABLE 133. IONIS PHARMACEUTICALS, INC: OPERATING SEGMENTS; TABLE 134. IONIS PHARMACEUTICALS, INC: PRODUCT PORTFOLIO; TABLE 135. IONIS PHARMACEUTICALS, INC: KEY STRATEGIC MOVES AND DEVELOPMENTS; FIGURE 1. GLOBAL AGE RELATED MACULAR DEGENERATION MARKET, 2024 - 2033; FIGURE 2. SEGMENTATION OF AGE RELATED MACULAR DEGENERATION MARKET, 2024 - 2033; FIGURE 3. TOP INVESTMENT POCKET IN AGE RELATED MACULAR DEGENERATION MARKET; FIGURE 4. MODERATE BARGAINING POWER OF BUYERS; FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS; FIGURE 6. MODERATE THREAT OF NEW ENTRANTS; FIGURE 7. LOW THREAT OF SUBSTITUTION; FIGURE 8. HIGH COMPETITIVE RIVALRY; FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALAGE RELATED MACULAR DEGENERATION MARKET; FIGURE 10. GLOBAL AGE RELATED MACULAR DEGENERATION MARKET SEGMENTATION, BY DRUG TYPE; FIGURE 11. AGE RELATED MACULAR DEGENERATION MARKET FOR AFLIBERCEPT, BY COUNTRY, 2024 - 2033 ($BILLION); FIGURE 12. AGE RELATED MACULAR DEGENERATION MARKET FOR RANIBIZUMAB, BY COUNTRY, 2024 - 2033 ($BILLION); FIGURE 13. AGE RELATED MACULAR DEGENERATION MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION); FIGURE 14. GLOBAL AGE RELATED MACULAR DEGENERATION MARKET SEGMENTATION, BY DISEASE TYPE; FIGURE 15. AGE RELATED MACULAR DEGENERATION MARKET FOR WET AGE RELATED MACULAR DEGENERATION (AMD), BY COUNTRY, 2024 - 2033 ($BILLION); FIGURE 16. AGE RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION (AMD), BY COUNTRY, 2024 - 2033 ($BILLION); FIGURE 17. GLOBAL AGE RELATED MACULAR DEGENERATION MARKET SEGMENTATION, BY DISTRIBUTION CHANNEL; FIGURE 18. AGE RELATED MACULAR DEGENERATION MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2024 - 2033 ($BILLION); FIGURE 19. AGE RELATED MACULAR DEGENERATION MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2024 - 2033 ($BILLION); FIGURE 20. AGE RELATED MACULAR DEGENERATION MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2024 - 2033 ($BILLION); FIGURE 21. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*; FIGURE 22. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*; FIGURE 23. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*; FIGURE 24. PRODUCT MAPPING OF TOP 10 PLAYERS; FIGURE 25. COMPETITIVE DASHBOARD; FIGURE 26. COMPETITIVE HEATMAP: AGE RELATED MACULAR DEGENERATION MARKET; FIGURE 27. TOP PLAYER POSITIONING, 2023; FIGURE 28. REGENERON PHARMACEUTICALS INC.: NET SALES, 2021-2023 ($BILLION); FIGURE 29. REGENERON PHARMACEUTICALS INC.: REVENUE SHARE, BY SEGMENT, 2023 (%); FIGURE 30. REGENERON PHARMACEUTICALS INC.: REVENUE SHARE, BY REGION, 2023 (%); FIGURE 31. NOVARTIS AG: NET SALES, 2021-2023 ($BILLION); FIGURE 32. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2023 (%); FIGURE 33. NOVARTIS AG: REVENUE SHARE, BY REGION, 2023 (%); FIGURE 34. F. HOFFMANN-LA ROCHE LTD.: NET SALES, 2021-2023 ($BILLION); FIGURE 35. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%); FIGURE 36. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY REGION, 2023 (%); FIGURE 37. BIOGEN: NET SALES, 2021-2023 ($BILLION); FIGURE 38. BIOGEN: REVENUE SHARE, BY SEGMENT, 2023 (%); FIGURE 39. BIOGEN: REVENUE SHARE, BY REGION, 2023 (%); FIGURE 40. BAYER AG: NET SALES, 2021-2023 ($BILLION); FIGURE 41. BAYER AG: REVENUE SHARE, BY SEGMENT, 2023 (%); FIGURE 42. BAYER AG: REVENUE SHARE, BY REGION, 2023 (%); FIGURE 43. COHERUS BIOSCIENCES INC: NET SALES, 2021-2023 ($BILLION); FIGURE 44. COHERUS BIOSCIENCES INC: REVENUE SHARE, BY SEGMENT, 2023 (%); FIGURE 45. COHERUS BIOSCIENCES INC: REVENUE SHARE, BY REGION, 2023 (%); FIGURE 46. SANOFI: NET SALES, 2021-2023 ($BILLION); FIGURE 47. SANOFI: REVENUE SHARE, BY SEGMENT, 2023 (%); FIGURE 48. SANOFI: REVENUE SHARE, BY REGION, 2023 (%); FIGURE 49. APELLIS PHARMACEUTICALS: NET SALES, 2021-2023 ($BILLION); FIGURE 50. APELLIS PHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2023 (%); FIGURE 51. APELLIS PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2023 (%); FIGURE 52. BAUSCH HEALTH COMPANIES INC.: NET SALES, 2021-2023 ($BILLION); FIGURE 53. BAUSCH HEALTH COMPANIES INC.: REVENUE SHARE, BY SEGMENT, 2023 (%); FIGURE 54. BAUSCH HEALTH COMPANIES INC.: REVENUE SHARE, BY REGION, 2023 (%); FIGURE 55. IONIS PHARMACEUTICALS, INC: NET SALES, 2021-2023 ($BILLION); FIGURE 56. IONIS PHARMACEUTICALS, INC: REVENUE SHARE, BY SEGMENT, 2023 (%); FIGURE 57. IONIS PHARMACEUTICALS, INC: REVENUE SHARE, BY REGION, 2023 (%)